Clinical characteristics of the 13 patients studied
Patient . | Sex/age, y . | Symptoms . | Sézary cells, % . | Previous treatment . | Current treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | F/70 | Erythemato-squamous plaques, then erythroderma | 30 | TM, CS, Ch, PUVA | Ch + CS | PR |
| 2 | M/79 | Erythroderma | 70 | — | TM + Ch + MTX | PR, then DOD |
| 3 | M/75 | Erythroderma | 70 | TM, CS | Ch + TM + CS | PR, then DOD |
| 4 | F/44 | Erythroderma | 80 | TM, CS | Cytapheresis + IFN | PR, then relapse |
| 5 | M/64 | Erythroderma, pruritus, xerosis | 80 | Ch, CS | TM + ECP + IFN | DOD |
| 6 | M/62 | Erythroderma, pruritus | 50 | PUVA | ECP then ECP + IFN | LTF |
| 7 | M/62 | Erythroderma, PPK | 95 | TM, CS, cytapheresis | ECP | PR, then relapse |
| 8 | F/71 | Erythroderma | 90 | TM, CS | TM | LTF |
| 9 | M/54 | Erythroderma | 10 | IFN | IFN | PR |
| 10 | M/66 | Erythroderma | 80 | ECP | Al | CR |
| 11 | F/75 | Annular erythematous lesions, then erythroderma, pruritus, xerosis, | 35 | Cytapheresis, TM, PUVA, IFN | ECP, then ECP + IFN | CR |
| 12 | M/60 | Erythroderma, pruritus, PPK, nail dystrophy | 50 | Cytapheresis, TM, PUVA, IFN | ECP, then ECP + IFN | Relapse |
| 13 | F/74 | Erythroderma | 60 | TM, CS, Ch | Cytapheresis | DOD |
Patient . | Sex/age, y . | Symptoms . | Sézary cells, % . | Previous treatment . | Current treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | F/70 | Erythemato-squamous plaques, then erythroderma | 30 | TM, CS, Ch, PUVA | Ch + CS | PR |
| 2 | M/79 | Erythroderma | 70 | — | TM + Ch + MTX | PR, then DOD |
| 3 | M/75 | Erythroderma | 70 | TM, CS | Ch + TM + CS | PR, then DOD |
| 4 | F/44 | Erythroderma | 80 | TM, CS | Cytapheresis + IFN | PR, then relapse |
| 5 | M/64 | Erythroderma, pruritus, xerosis | 80 | Ch, CS | TM + ECP + IFN | DOD |
| 6 | M/62 | Erythroderma, pruritus | 50 | PUVA | ECP then ECP + IFN | LTF |
| 7 | M/62 | Erythroderma, PPK | 95 | TM, CS, cytapheresis | ECP | PR, then relapse |
| 8 | F/71 | Erythroderma | 90 | TM, CS | TM | LTF |
| 9 | M/54 | Erythroderma | 10 | IFN | IFN | PR |
| 10 | M/66 | Erythroderma | 80 | ECP | Al | CR |
| 11 | F/75 | Annular erythematous lesions, then erythroderma, pruritus, xerosis, | 35 | Cytapheresis, TM, PUVA, IFN | ECP, then ECP + IFN | CR |
| 12 | M/60 | Erythroderma, pruritus, PPK, nail dystrophy | 50 | Cytapheresis, TM, PUVA, IFN | ECP, then ECP + IFN | Relapse |
| 13 | F/74 | Erythroderma | 60 | TM, CS, Ch | Cytapheresis | DOD |
TM indicates topical mechlorethamine; Ch, chlorambucil; PUVA, psoralen UVA photochemotherapy; —, none; CS, corticosteroid; ECP, extracorporeal photopheresis; IFN, interferon; MTX, methotrexate; Al, alemtuzumab; CR, complete remission; PR, partial remission; DOD, died of disease; LTF, lost to follow-up.